Last reviewed · How we verify
A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma
This is a Phase 2 study during which patients with advanced multiple myeloma will receive either carfilzomib alone (single-agent) or carfilzomib in combination with investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of both single-agent carfilzomib and carfilzomib + filanesib in treating myeloma. Patients will be allowed to crossover from single-agent carfilzomib to carfilzomib + filanesib if disease progression occurs. Approximately 75 patients from the US will be enrolled in this study.
Details
| Lead sponsor | Pfizer |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 77 |
| Start date | 2013-11 |
| Completion | 2016-05 |
Conditions
- Advanced Multiple Myeloma
Interventions
- Carfilzomib, proteasome inhibitor; intravenous
- Filanesib, KSP(Eg5) inhibitor; intravenous
- Dexamethasone, steroid; oral or intravenous
- Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Primary outcomes
- Assess the efficacy of both carfilzomib + study drug and single-agent carfilzomib in terms of progression-free survival. — 18 months
Countries
United States